STOCK TITAN

vTv Therapeutics (VTVT) Financials

VTVT NASDAQ
Trailing 12 months to September 30, 2026
Revenue $36.8M +216600.0% YoY
Net Income -$7.7M n/m YoY
EPS (Diluted) Not reported for the trailing 12 months
Operating Cash Flow -$21.7M n/m YoY
Market Cap $62.2M as of Nov 20, 2026
Price / Sales 1.7x on $36.8M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.9x on $69.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VTVT SEC filings page.

vTv Therapeutics Inc. (VTVT) reported $36.8M in revenue over the twelve months to Sep 30, 2026, up 216600.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VTVT FY2025

Development spending drives the business, while recurring operating losses are financed mainly through external capital rather than operating cash.

FY2025 operating cash flow was -$25.3M against a net loss of $27.0M, showing that reported losses closely tracked cash consumption rather than being mainly non-cash. Financing supplied $77.4M alongside that operating cash outflow, making capital raising the main cash source for the period.

The cost structure remains development-led rather than commercial: in FY2024, R&D was $11.5M against $1.0M of revenue, so research spending outweighed sales by a wide margin. SG&A added another $13.7M, indicating that the loss reflects a broad operating platform, not only laboratory investment.

Financing reshaped the balance sheet: equity moved from -$24.7M in FY2023 to $64.4M in FY2025, changing the reported position from negative equity to a positive cushion. Liabilities fell from 324.0% of assets to 28.3%, so the company became less balance-sheet burdened even as operating losses continued.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for vTv Therapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-3.71

vTv Therapeutics Inc. scores -3.71, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $326.7M against total assets of $89.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/7

vTv Therapeutics Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

vTv Therapeutics Inc. reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

vTv Therapeutics Inc. reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0
YoYn/m
QoQn/m

vTv Therapeutics Inc. generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA
-$12.4M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

vTv Therapeutics Inc.'s EBITDA was -$12.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$11.6M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

vTv Therapeutics Inc. reported a net loss of $11.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$77.2M
YoY-21.7%
QoQ-10.9%
5Y CAGR+31.6%
10Y CAGR+4.2%

vTv Therapeutics Inc. held $77.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
4M
YoY+1.9%
QoQ+1.5%

vTv Therapeutics Inc. had 4M shares outstanding in Q3 2026. This represents an increase of 1.9% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-16.7%
YoY-4.3pp
QoQ-0.1pp

vTv Therapeutics Inc.'s quarterly ROE was -16.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 4.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$7.5M
YoY+7.3%
QoQ-14.1%
5Y CAGR+25.9%

vTv Therapeutics Inc. invested $7.5M in research and development in Q3 2026. This represents an increase of 7.3% from the same quarter a year earlier. Against the prior quarter it is down 14.1%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

VTVT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VTVT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$0n/m$0n/m$36.8Mn/m$0-100.0%$0n/m$0n/m$0-100.0%$17Kn/m
R&D Expenses$7.5M+7.3%$8.8M+113.7%$9.0M+217.2%$3.9M+74.9%$7.0M+117.7%$4.1M+19.3%$2.8M+6.8%$2.2M+4.5%
SG&A Expenses$4.9M+33.1%$5.2M+42.6%$4.6M+25.2%$4.0M+48.7%$3.7M+12.1%$3.6M-2.6%$3.7M-7.7%$2.7M+4.1%
Operating Income-$12.4Mn/m-$13.9Mn/m$23.3Mn/m-$7.9Mn/m-$10.7Mn/m-$7.7Mn/m-$6.5Mn/m-$4.9Mn/m
EBITDA-$12.4Mn/m-$13.9Mn/m$23.3Mn/m-$7.9Mn/m-$10.7Mn/m-$7.7Mn/m-$6.5Mn/m-$4.9Mn/m
Interest ExpenseN/AN/AN/AN/A$5Kn/mN/AN/AN/A
Income Tax$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%$0n/m
Net Income-$11.6Mn/m-$13.1Mn/m$24.1Mn/m-$7.1Mn/m-$8.7Mn/m-$6.0Mn/m-$5.1Mn/m-$3.6Mn/m

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

VTVT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VTVT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$78.6M-21.0%$87.6M+231.2%$98.8M+208.5%$89.9M+134.9%$99.5M+130.5%$26.4M-43.1%$32.0M-40.9%$38.3M+247.3%
Current Assets$78.6M-21.0%$87.6M+232.1%$98.8M+209.6%$89.9M+135.9%$99.5M+131.5%$26.4M-42.9%$31.9M-40.8%$38.1M+257.6%
Cash & Equivalents$77.2M-21.7%$86.6M+234.2%$98.1M+215.8%$88.9M+142.0%$98.5M+137.0%$25.9M-43.1%$31.1M-40.6%$36.7M+289.0%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0
Accounts ReceivableN/AN/AN/AN/AN/AN/AN/A$62K-39.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$8.9M-69.2%$9.0M-62.7%$8.9M-61.7%$25.5M+6.2%$29.0M+14.7%$24.0M-7.6%$23.1M-18.0%$24.0M-32.9%
Current Liabilities$7.0M-30.9%$7.0M+32.5%$6.9M+59.4%$6.6M+27.8%$10.2M+58.2%$5.3M-24.2%$4.3M-51.6%$5.2M-51.1%
Non-Current Liabilities$1.9M-89.9%$1.9M-89.6%$2.0M-89.5%$18.8M+0.3%$18.8M-0.2%$18.7M-1.5%$18.8M-2.4%$18.8M-25.2%
Total Equity$69.7M-1.2%$78.6M+2746.9%$90.0M+1035.8%$64.4M+428.2%$70.5M+370.0%$2.8M-83.2%$7.9M-61.9%$12.2Mn/m
Retained Earnings-$327.2Mn/m-$315.6Mn/m-$302.6Mn/m-$326.7Mn/m-$319.6Mn/m-$310.9Mn/m-$304.8Mn/m-$299.7Mn/m

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

VTVT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VTVT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$10.2Mn/m-$11.4Mn/m$9.2Mn/m-$9.3Mn/m-$5.2Mn/m-$5.1Mn/m-$5.7Mn/m-$4.8Mn/m
Depreciation & Amortization$1K-50.0%$1K-66.7%$1K-88.9%$2K-90.9%$2K-90.9%$3K-87.0%$9K-59.1%$22K-4.3%
Stock-Based Compensation$2.0M+95.1%$1.7M+85.7%$1.4M+70.7%N/A$1.0M+18.1%$930K+8.3%$813K+269.5%N/A
Financing Cash Flow$709K-99.1%N/AN/A-$321Kn/m$77.8M+3058.9%-$42Kn/m$0-100.0%$0n/m

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

VTVT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VTVT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating MarginN/AN/A63.1%N/AN/AN/AN/A-28776.5%
Net MarginN/AN/A65.5%N/AN/AN/AN/A-21376.5%
Return on Equity-16.7%-4.3pp-16.6%+202.3pp26.8%+91.1pp-11.1%+18.7pp-12.3%+19.5pp-218.9%-187.5pp-64.3%-40.9pp-29.8%
Return on Assets-14.8%-6.0pp-14.9%+8.0pp24.4%+40.3pp-7.9%+1.6pp-8.7%+2.3pp-22.9%-11.7pp-15.9%-6.9pp-9.5%+22.1pp
Current Ratio11.19+1.4x12.48+7.5x14.36+7.0x13.54+6.2x9.79+3.1x4.98-1.6x7.39+1.4x7.34+6.3x
Liabilities-to-Equity0.13-0.3x0.11-8.6x0.10-2.8x0.40-1.6x0.41-1.3x8.70+7.1x2.92+1.6x1.96
Asset Turnover0.000.0x0.000.0x0.37+0.4x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
vTv Therapeutics Inc. VTVT FY2025 $0 -$27.0M N/A $62.2M —
Coherus Oncology, Inc. CHRS FY2025 $42.2M $168.0M N/A $57.1M 30/100
Tenaya Therapeutics, Inc. TNYA FY2025 N/A -$90.6M N/A $65.3M —
Tenax Therapeutics, Inc. TENX FY2025 $0 -$52.6M N/A $56.9M —
Coya Therapeutics, Inc. COYA FY2025 $7.9M -$21.2M N/A $69.2M 64/100
TuHURA Biosciences, Inc. HURA FY2025 $0 -$30.1M N/A $82.2M —

Frequently Asked Questions

vTv Therapeutics Inc. (VTVT) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

vTv Therapeutics Inc. (VTVT) revenue declined by 100.0% year-over-year, from $1.0M to $0 in fiscal year 2025.

No, vTv Therapeutics Inc. (VTVT) reported a net loss of $7.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $27.0M.

vTv Therapeutics Inc. (VTVT) had EBITDA of -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

vTv Therapeutics Inc. (VTVT) has a return on equity of -41.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

vTv Therapeutics Inc. (VTVT) recorded an outflow of $25.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

vTv Therapeutics Inc. (VTVT) had $89.9M in total assets as of fiscal year 2025, including both current and long-term assets.

vTv Therapeutics Inc. (VTVT) invested $17.9M in research and development during fiscal year 2025.

vTv Therapeutics Inc. (VTVT) had 4M shares outstanding as of fiscal year 2025.

vTv Therapeutics Inc. (VTVT) had a current ratio of 13.54 as of fiscal year 2025, which is generally considered healthy.

vTv Therapeutics Inc. (VTVT) had a liabilities-to-equity ratio of 0.40 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

vTv Therapeutics Inc. (VTVT) had a return on assets of -30.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

vTv Therapeutics Inc. (VTVT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $62.2M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

vTv Therapeutics Inc. (VTVT) trades at 1.7x sales, its market capitalization divided by $36.8M revenue, trailing 12 months to September 30, 2026. The market capitalization is $62.2M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, vTv Therapeutics Inc. (VTVT) held $88.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $25.3M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

vTv Therapeutics Inc. (VTVT) has an Altman Z-Score of -3.71, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

vTv Therapeutics Inc. (VTVT) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

vTv Therapeutics Inc. (VTVT) reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

vTv Therapeutics Inc. (VTVT) reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top